Literature DB >> 33825035

Use of cucurbitacins for lung cancer research and therapy.

Min Liu1, Qijia Yan2, Bi Peng2, Yuan Cai2, Shuangshuang Zeng1, Zhijie Xu2, Yuanliang Yan3, Zhicheng Gong4,5.   

Abstract

As the main substance in some traditional Chinese medicines, cucurbitacins have been used to treat hepatitis for decades in China. Currently, the use of cucurbitacins against cancer and other diseases has achieved towering popularity among researchers worldwide, as detailed in this review with summarized tables. Numerous studies have reported the potential tumor-killing activities of cucurbitacins in multiple aspects of human malignancies. Continuous research on its anticancer activity mechanisms also brings a glimmer of light to the treatment of patients with lung cancer. In line with the promising roles of cucurbitacins against cancer, through various molecular signaling pathways, it is justifiable to propose the use of cucurbitacins as a potential mainline chemotherapy before the onset and after the diagnosis of lung cancers. Here, this article mainly summarized the findings about the biological functions and underlying mechanisms of cucurbitacins on lung cancer pathogenesis and treatment. In addition, we also discussed the safety and efficacy of their application for further research and even clinical practice.

Entities:  

Keywords:  Cucurbitacins; Lung cancer; Mechanisms; Traditional Chinese medicine; Treatment

Year:  2021        PMID: 33825035     DOI: 10.1007/s00280-021-04265-7

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  117 in total

1.  Lung cancer staging: imagine fewer images.

Authors:  Ivan Vollmer; Marcelo Sánchez; Ramón Rami-Porta
Journal:  Eur Respir J       Date:  2018-08-09       Impact factor: 16.671

Review 2.  The biology and management of non-small cell lung cancer.

Authors:  Roy S Herbst; Daniel Morgensztern; Chris Boshoff
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

3.  Identification of CAV1 and DCN as potential predictive biomarkers for lung adenocarcinoma.

Authors:  Yuanliang Yan; Zhijie Xu; Long Qian; Shuangshuang Zeng; Yangying Zhou; Xi Chen; Jie Wei; Zhicheng Gong
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-01-03       Impact factor: 5.464

4.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

5.  Radiosensitizing effect of diosmetin on radioresistant lung cancer cells via Akt signaling pathway.

Authors:  Zhijie Xu; Yuanliang Yan; Lingfang Xiao; Shuang Dai; Shuangshuang Zeng; Long Qian; Lin Wang; Xue Yang; Yi Xiao; Zhicheng Gong
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

6.  Dasatinib Inhibits Lung Cancer Cell Growth and Patient Derived Tumor Growth in Mice by Targeting LIMK1.

Authors:  Man Zhang; Jie Tian; Rui Wang; Mengqiu Song; Ran Zhao; Hanyong Chen; Kangdong Liu; Jung-Hyun Shim; Feng Zhu; Zigang Dong; Mee-Hyun Lee
Journal:  Front Cell Dev Biol       Date:  2020-12-04

7.  Comprehensive Molecular Characterizations of Chinese Patients With Different Subtypes of Lung Squamous Cell Carcinoma.

Authors:  Jie Qian; Rongrong Chen; Ruiying Zhao; Yuchen Han; Yongfeng Yu
Journal:  Front Oncol       Date:  2020-12-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.